Greenwood Capital Associates’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-3,490
Closed -$924K – 231
2021
Q4
$924K Buy
3,490
+60
+2% +$16.2K 0.13% 132
2021
Q3
$991K Buy
3,430
+107
+3% +$27.4K 0.15% 109
2021
Q2
$663K Buy
3,323
+86
+3% +$16.7K 0.1% 158
2021
Q1
$629K Buy
3,237
+229
+8% +$47K 0.1% 158
2020
Q4
$576K Buy
3,008
+524
+21% +$95.3K 0.1% 153
2020
Q3
$366K Buy
2,484
+422
+20% +$60.3K 0.07% 153
2020
Q2
$255K Sell
2,062
-584
-22% -$68.7K 0.06% 157
2020
Q1
$255K Sell
2,646
-141
-5% -$13.6K 0.07% 120
2019
Q4
$258K Buy
+2,787
New +$234K 0.05% 165

Other funds holding RGEN

Greenwood Capital Associates's RGEN Position: Q1 2022 in Review

Greenwood Capital Associates sold out of Repligen (RGEN) in Q1 2022, closing a stake of 3,490 shares — an estimated $924K sold.

Greenwood Capital Associates first reported a position in RGEN in Q4 2019 and held it in 9 quarters. The position peaked at $991K in Q3 2021. 450 funds tracked by Wall St. Rank hold RGEN as of Q1 2022.

  • Greenwood Capital Associates reported no remaining Repligen position as of Q1 2022 after selling out during the quarter.
  • Greenwood Capital Associates sold 3,490 Repligen shares in Q1 2022, an estimated $924K.
  • Greenwood Capital Associates first reported a position in Repligen in Q4 2019 and held it in 9 quarters.
  • Greenwood Capital Associates's Repligen position peaked at $991K in Q3 2021.
  • 450 funds tracked by Wall St. Rank held Repligen as of Q1 2022.

Based on Greenwood Capital Associates's 13F filing for Q1 2022, filed 10 May 2022.